3 COVID Vaccine Stocks That Can Be Millionaire-Makers


Some investors have made a lot of money this year on stocks of companies developing vaccines of coronovirus. Many of these stocks have risen hundreds of percent in a relatively short period of time. And this has happened before any COVID-19 vaccine won the Emergency Use Authority or regulatory approval.

There is still a lot of money for investors in the race for the coronavirus vaccine. These three COVID vaccine stocks could potentially be millionaire-makers as well.

Image Source: Getty Image

1. Modern

Moderna (NASDAQ: mRNA) In fact with its COVID-19 vaccine mRNA-1273 appears to be close to reaching the market. Biotech reported a few weeks ago of excellent efficacy results for the experimental vaccine. Assuming that there are no road faults, the modern December could win the Emergency Use Authority for mRNA-1273.

The influx of cash will soon be poured into Modern’s Coffer. Biotech has supply agreements in hand for over 330 million doses. While the financial details of all its supply deals have not been announced, the combined price tag for these agreements probably topped $ 6 billion and could be much higher.

However, mRNA-1273 is not expected to keep modernity in the millionaire stock. The market cap of biotech already shows great potential for the COVID-19 vaccine. The success of mRNA-1273, however, could go well for the rest of Modern’s pipelines – and simply allow investors to buy stocks that can become millionaires over time.

Modern thinks its messenger RNA (mRNA) technology can be used in vaccines and therapies that target a myriad of diseases. The company now has a dozen mRNA programs in its pipeline. Chief Executive Officer Stephen Bansell said he expected mRNA-1273 supply deals to expand the pipeline to up to 50 mRNA programs in clinical trials. This is a multiplier effect that can make modern shareholders very wealthy if many of these candidates are successful.

2. Novaxax

Although the modern coronovirus ranks as one of the clear leaders in the vaccine race, the biotech stock has not given the biggest gains so far this year. Whose honor is that Novavax (NASDAQ: NVAX): Its shares have skyrocketed over 3,000% year to date.

Novax is currently undergoing a late-stage clinical study for its COVID-19 vaccine candidate, NVX-CoV2373. The company plans to begin a US-level study of the experimental vaccine by the end of November. It has already drawn up agreements with Australia, Canada, and the UK, which will supply a total of 176 million doses of NVX-CoV2373 if all goes well. In addition, Novavax signed a $ 1.6 billion deal with Operation Warp Speed ​​that included 100 million doses of supplies to the US.

In addition to its promising coronovirus vaccine, Novax also has an influenza vaccine candidate, Nanoflu, which may be headed for approval by the Food and Drug Administration. Biotech announced excellent results earlier this year from a late stage study of nanoflu. The main hurdle to the jump is now too much stability to demonstrate that the company’s manufacturing processes are in order.

Despite its big gains this year, Novavax has a market cap of about $ 6 billion. With two possible blockbuster vaccines in the wings, the stock can grow very high.

3. Waxart

Vaxart (NASDAQ: VXRT) Clinical trials of its COVID-19 vaccine candidate, VXA-CoV2-1, have almost no. However, the stock has gained nearly 1,900% compared to this year, being the biggest winner.

Biotech is currently evaluating VXA-CoV2-1 in Phase I clinical studies. Waxart completed enrollment in the study earlier this month and may report preliminary results within the next few weeks.

Could it be late for the Waxart party to achieve success for VXA-CoV2-1? Not necessary. There is something unique about the VXA-CoV2-1 that can be a game-changer: it is a single-dose tablet. All are injections of major coronovirus vaccine candidates, most of which require two doses, which vary over several weeks.

If VXA-CoV2-1 proves to be safe and effective, then Vaxart may have great opportunities to target other viral diseases along with oral virals. With a market cap of less than $ 750 million, investors can still make a fortune with the stock if all goes well in Waxert’s clinical studies.

Don’t count your money yet

These three COVID vaccine stocks have already yielded massive gains and may have considerable space. But don’t count your money yet.

Waxart is apparently the most at-risk for the group as it is still in early stage trials. However, Modern and Novavax are risky. There are still significant hurdles for each biotech to jump.

The ability of any stock to make a lot of money comes at the hip causing a lot of money to be lost. Investors must weigh the risks against potential rewards before purchasing any stock – even those that may be millionaire-makers.

Leave a Reply